Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Andrew Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Videos

Zanubrutinib Plus Obinutuzumab and Venetoclax With MRD-Driven Discontinuation Shows Promise in CLL/SLL

05/14/2022

Andrew Zelenetz, MD, PhD, discusses results from a phase 2 trial assessing triplet therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated CLL or SLL and exploring MRD as a biomarker for treatment duration.

Andrew Zelenetz, MD, PhD,...

05/14/2022

Oncology

Videos

Successful Manufacturing of Lisocabtagene Maraleucel for Patients With CLL

04/18/2022

Tanya Siddiqi, MD, shares results and insights of the TRANSCEND CLL 004 study of lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy for patients with CLL.

Tanya Siddiqi, MD, shares...

04/18/2022

Oncology

Podcasts

Ibrutinib Improves Outcomes Over Rituximab Among Patients With Advanced CLL/SLL

04/06/2022

Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.

Shenmiao Yang, MD, highlights a...

04/06/2022

Oncology

Videos

Dr Gale Highlights Transplants, Cell Therapies for CLL

03/14/2022

Robert Peter Gale, MD, PhD, DSc (Hon), FACP, FRCP, FRSM, highlights transplants and cell therapies, including HCT and CAR T-cells, for patients with CLL.

Robert Peter Gale, MD, PhD, DSc...

03/14/2022

Oncology

Videos

Dr Burger Overviews the Activation, Expansion of T Follicular Helper Cells in CLL

03/10/2022

Jan A. Burger, MD, PhD, highlights a study on the activation and expansion of T follicular helper cells in co-cultures of patients with CLL.

Jan A. Burger, MD, PhD,...

03/10/2022

Oncology

Videos

Dr Lee Reviews Cirmtuzumab and Ibrutinib in MCL/CLL

03/02/2022

Hun Ju Lee, MD, reviews a phase 1b/2 study of cirmtuzumab and ibrutinib for patients with MCL or CLL.

Hun Ju Lee, MD, reviews a phase...

03/02/2022

Oncology

Videos

Dr Tam Overviews Zanubrutinib Versus Bendamustine-Rituximab in CLL/SLL

02/24/2022

Constantine Tam, MD, overviews results from the phase 3 SEQUOIA study on zanubrutinib versus bendamustine-rituximab in patients with treatment-naïve CLL/SLL, presented at ASH 2021.

Constantine Tam, MD, overviews...

02/24/2022

Oncology

Videos

Dr Tedeschi Reviews Zanubrutinib Plus Venetoclax for Patients With CLL

02/11/2022

Alessandra Tedeschi, MD, reviews early results from arm D of the SEQUOIA trial on zanubrutinib in combination with venetoclax for patients with treatment-naïve CLL or SLL with del(17p) aberrations.

Alessandra Tedeschi, MD, reviews...

02/11/2022

Oncology

Videos

Dr Shadman Discusses Safety and Efficacy of Third Generation CD20 Targeted CAR-T for R/R B-NHL, CLL

01/10/2022

Mayzar Shadman, MD, MPH, discusses the safety and efficacy of a third-generation CD20-targeted CAR-T therapy for relapsed/refractory B-NHL and CLL, presented at ASH 2021.

Mayzar Shadman, MD, MPH,...

01/10/2022

Oncology

Videos

James Dean, MD, PhD, Shares MRD Outcomes of Ibrutinib Plus Venetoclax for First-Line Treatment of CLL

01/04/2022

Dr Dean discusses minimal residual disease outcomes after fixed-duration ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab for first-line treatment of CLL.

Dr Dean discusses minimal...

01/04/2022

Oncology

Chronic Lymphocytic Leukemia Excellence Forum

Specialties

Events

Year Round Education

HMP Global Products